Investment
Features
FeesSafety
Academy
More
Pluang+

Compare SPDR Gold Trust (GLD) vs Smith & Nephew plc (SNN) Price & Performance

SPDR Gold TrustTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

SPDR Gold Trust vs Smith & Nephew plc — how do they compare? SPDR Gold Trust trades at $365.55, while Smith & Nephew plc trades at $31.3 (market cap $12.81B). The key difference: Smith & Nephew plc pays a 2.54% dividend while SPDR Gold Trust pays none. Which is the better fit depends on your goals.

GLDSNN
52-Week High
$495.90$38.70
52-Week Low
$300.96$28.73
Market Cap
$12.81B
Sector
Health
Enterprise Value
$15.58B
Dividend Yield
2.54%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

SPDR Gold Trust

GLD (SPDR Gold Shares ETF) trades at $365.75, down 1.72% amid bearish technical signals with 14 sell indicators. The ETF tracks physical gold prices, currently facing pressure from stabilizing dollar and rate-hike expectations. Recent economic data shows mixed signals with cooling inflation but strong labor market data weighing on gold prices. The fund provides direct exposure to gold bullion with lower volatility compared to mining stocks.

Gold's near-term outlook faces headwinds from potential Fed rate policy and dollar strength, though geopolitical tensions and central bank accumulation provide support. The technical picture suggests consolidation near key support levels with bearish momentum indicators. Investors should monitor Fed policy signals and inflation data for directional catalysts.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $31.41, up 5.28% today, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $5.8B in 2024 to $6.2B projected for 2025 and net income margin expanding to 10.14%. Recent product launches in robotics and wound care, plus a $500M share buyback, highlight strategic execution. Analyst consensus is mixed with 27% buy ratings but 68% hold, reflecting cautious optimism amid earnings volatility where two of the last four quarters missed expectations.

Outlook: SNN's recovery trajectory and product innovation support long-term growth, but investor patience is needed due to earnings inconsistency and moderate debt levels. Key risks include competitive pressures in medtech and execution on guidance. The stock presents a value opportunity if operational improvements continue, trading at reasonable valuations (P/E 21.5, P/S 2.18) versus sector peers.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About SPDR Gold Trust

GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.

Read more on GLD

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN